Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Investigating the Role of DNp63 in breast cancer

ABSTRACT: The goal of this study was to characterize the differences in the global binding affinity of DNp63 to different genomic regions and its downstream target genes in human breast xenograft tumors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE144995 | GEO | 2020/08/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Investigating the Role of DNp63 in breast cancer

Project description:Investigating the Role of DNp63 in breast cancer

| PRJNA605649 | ENA

Investigating the altered brain metastatic transcriptome in breast cancer

Project description:Brain metastatic disease occurs in 10-30% of metastatic breast cancer cases. The incidence of brain metastases is increasing with median overall survival < 2 years for patients. In order to better characterize oncogenic pathway activity pertinent to breast cancer brain metastasis, exome capture RNA sequencing was carried out on patient matched primary breast with brain metastatic tumor samples for 45 cases of breast cancer brain metastasis (N= 90 samples). Here, exome capture RNA sequencing data is deposited as sequencing batch corrected log2 transformed trimmed M of means (TMM) normalized counts per million (CPM) (log2(TMM-CPM +1) gene expression values (n=16,714 protein coding genes; N=90 tumor samples).

2022-04-01 | GSE173661 | GEO

Investigating the altered brain metastatic transcriptome in breast cancer

2021-11-12 | GSE184869 | GEO

Breast Cell Lines: Experimental vs. Mixed Reference

Project description:Transcriptional profiling of breast cell lines comparing breast cell line mixed reference with individual breast cell lines. Goal was to characterize breast cell line subtypes.

2009-10-10 | GSE18496 | GEO

Heterogeneity of Breast Cancer Vasculature

Project description:Tumor-associated breast vasculature was laser-cappture microdissected from IDC breast cancer cases. The goal of the study was to characterize the heterogeneity of breast tumor-associated vasculature and identify gene expression signatures predictive of clinical outcome.

2010-09-19 | GSE15363 | GEO

Characterization of estrogen regulation in estrogen reseptor (ER)-positive breast cancer at the single cell level

Project description:We performed the single-cell analysis to characterize estrogen regulation in ER-positive breast cancer using patient-derived xenograft (PDX) model (named SC31).

2021-12-09 | GSE176532 | GEO

Heterogeneity of Breast Cancer Vasculature

2010-09-19 | E-GEOD-15363 | biostudies-arrayexpress

Tumor-associated stroma derived from primary clinical breast cancer samples

Project description:Tumor-associated breast stroma was laser-capture microdissected from IDC breast cancer cases. The goal of the study was to characterize the heterogeneity of breast tumor-assocaited stroma and identify gene expression signatures predictive of clinical outcome. Keywords: disease state analysis

2008-04-11 | GSE9014 | GEO

Gene expression pattern in CXCR4+ and CXCR4- subpopulation of breast cancer cells

Project description:The goal of this study was to identify signaling molecules downstream of CXCR4 in breast cancer cells. For this purpose, we sorted CXCR4-positive and CXCR4-negative cells from MDA-MB-231 breast cancer cell line by flow cytometry and performed microarrays analysis.

2010-04-20 | GSE15893 | GEO

Investigating the role of ERBB2 during colorectal cancer in the ApcMin/+ mouse model

Project description:The ERBB family consists of four receptors (EGFR, ERBB2, ERBB3, and ERBB4) that are critical in normal development and physiology of mammalian gastrointestinal epithelial tissues. Amplifications or mutations in ERBB2 are commonly found in CRC, suggesting a possible therapeutic target. Patients with ERBB2-amplification in breast and gastroesophageal cancer are routinely treated with the ERBB2-directed antibody trastuzumab. However, ERBB2 is not commonly targeted in clinical practice of treating CRC. Notably, ERBB2 status could guide therapy as a negative marker for EGFR-targeted therapy (cetuximab) and identify likely responders for ERBB2-directed therapy. Although the most common marker for negative efficacy of anti-EGFR therapy is KRAS mutations, many patients with KRAS wild-type tumors do not respond to EGFR inhibition. As the primary EGFR-directed antibodies for CRC do not inhibit ERBB2, alterations increasing ERBB2 may serve as a superior negative predictor of EGFR therapy since previous studies demonstrate that ERBB2 amplification confers resistance to cetuximab in preclinical models. Despite the compelling evidence, the utility of ERBB2 as a target for molecular therapy of primary CRC tumors in preclinical models is largely unexplored. As such, our goal is to further characterize the influece of ERBB2 in the initiation and progression of CRC.

2024-08-16 | GSE241084 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data